GlassScriptPhysician profile
Heather Hofstra
NPI 1255748950
$9,085.06
in general payments reported to CMS, 2019-2025
56 companies · $352 in 2025
The $352 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,110 · 2022: $2,499 · 2023: $1,894 · 2024: $2,231 · 2025: $352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,476.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $1,290.82 | 2021-2025 | Vumerity, Tysabri, Avonex |
| Abbvie INC. | $963.28 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $766.32 | 2021-2024 | |
| Neurocrine Biosciences, INC. | $572.64 | 2021-2023 | Ingrezza |
| Celgene Corporation | $534.49 | 2021-2025 | Zeposia |
| Teva Pharmaceuticals USA, INC. | $414.59 | 2022-2024 | Austedo, Austedo Xr |
| Livanova USA, INC. | $394.47 | 2021-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Janssen Pharmaceuticals, INC | $349.68 | 2021-2022 | |
| Catalyst Pharmaceuticals, INC. | $336.60 | 2024 | |
| Genzyme Corporation | $330.35 | 2021-2024 | |
| Acorda Therapeutics, INC | $291.95 | 2021-2024 | Ampyra, Inbrija |
| Alexion Pharmaceuticals, INC. | $177.41 | 2022-2024 | Ultomiris |
| Emd Serono, INC. | $175.43 | 2022-2023 | Mavenclad |
| Avadel Cns Pharmaceuticals, LLC | $174.83 | 2024 | Lumryz |
| Lundbeck LLC | $173.75 | 2021-2024 | Vyepti, Rexulti |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Hofstra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.